AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Sponsored Reports
Loading...
| Previous Close (in USD) | 4.19 |
|---|---|
| Change | -0.150 3.580% |
| 52 W H/L (in USD) | 1.290/0.307 |
| EBITDA (in USD) | -17.247M |
| PE Ratio | -- |
| Volume | 43794 |
| Diluted Eps TTM | -0.47 |
| Total Assets (in USD) | 20.724M |
|---|---|
| Total Liabilities (in USD) | 14.855M |
| Revenue TTM (in USD) | 2.293M |
| Cash (in USD) | 9.266M |
| Market Cap (in USD) | 25.177 M |
| Revenue Per Share TTM | 0.058 |
| Gross Profit TTM (in USD) | 1.421M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Femasys Inc
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Employees: 51
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Ms. Kathy Lee-Sepsick | Founder & CEO and Pres | 1967 |
| 2. | Mr. Daniel Scott Currie | SVP of Operations & Sec. | 1964 |
| 3. | Mr. Dov Elefant | Chief Financial Officer | 1967 |
| 4. | Ms. Mary An Merchant J.D., Ph.D. | VP of Counsel & Intellectual Property | NA |
| 5. | Mr. Steven P. Damon | VP of Bus. Devel. | 1956 |
| 6. | Mr. Todd A. Creech MBA | Chief Financial Advisor | 1968 |
| 7. | Dr. Jeffrey Marcus M.D., M.S. | Chief Medical Advisor | NA |
| 8. | Dr. Edward G. Evantash M.D. | Chief Medical Officer | 1963 |
| 9. | Ms. Christine Thomas | Sr. VP of Regulatory & Clinical Affairs | NA |
| 10. | Ms. Kathy Lee-Sepsick M.B.A. | Founder, President, CEO & Director | 1969 |
Peers
Sector: Healthcare
Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ISRG
Intuitive Surgical Inc |
+4.600 1.144% | 403.6 | 73.050 | 61.728 | 19.145 | 10.247 | 18.408 | 59.920 |
|
ESLOF
EssilorLuxottica Société anonyme |
0.000 0.000% | 205 | 44.840 | 27.624 | 4.068 | 2.492 | 3.715 | 16.038 |
|
ESLOY
Essilor International SA |
0.000 0.000% | 100.13 | 41.680 | 27.248 | 3.943 | 2.454 | 3.715 | 16.038 |
|
BDX
Becton Dickinson and Company |
+2.370 1.674% | 142.02 | 25.560 | 12.484 | 2.589 | 1.763 | 2.890 | 12.552 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -18.627M | -18.807M | -14.243M | -11.388M | -7.534M |
| Minority Interest | - | - | - | - | - |
| Net Income | -18.628M | -18.817M | -14.247M | -11.394M | -7.538M |
| Selling General Administrative | 6.646M | 6.326M | 6.858M | 5.431M | 4.262M |
| Gross Profit | 1.421M | 1.084M | 0.692M | 0.764M | 0.809M |
| Reconciled Depreciation | 0.85M | 0.872M | 0.879M | 0.889M | 0.964M |
| Ebit | -16.735M | -17.203M | -14.077M | -11.6M | -8.337M |
| Ebitda | -15.885M | -16.331M | -13.169M | -10.813M | -6.924M |
| Depreciation And Amortization | 0.85M | 0.872M | 0.908M | 0.787M | 1.413M |
| Operating Income | -17.589M | -17.786M | -14.508M | -11.6M | -8.337M |
| Other Operating Expenses | 19.882M | 19.415M | 15.58M | 12.806M | 9.516M |
| Interest Expense | 1.891M | 1.604M | 0.165M | 0.013M | 0.019M |
| Tax Provision | 0.001M | 0.01M | 0.004M | 0.006M | 0.004M |
| Interest Income | 0.102M | 0.582M | 0.351M | 0.228M | 0.004M |
| Net Interest Income | -1.789M | -1.021M | 0.337M | 0.215M | -0.015M |
| Income Tax Expense | 0.001M | 0.01M | 0.004M | 0.006M | 0.004M |
| Total Revenue | 2.293M | 1.629M | 1.072M | 1.206M | 1.18M |
| Total Operating Expenses | 19.01M | 18.87M | 15.2M | 12.365M | 9.146M |
| Cost Of Revenue | 0.872M | 0.545M | 0.38M | 0.442M | 0.37M |
| Total Other Income Expense Net | -1.038M | -1.021M | 0.266M | 0.212M | 0.803M |
| Net Income From Continuing Ops | -18.628M | -18.817M | -12.731M | -11.394M | -7.538M |
| Net Income Applicable To Common Shares | - | - | - | -11.394M | -7.538M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 20.724M | 12.445M | 27.756M | 16.896M | 28.577M |
| Intangible Assets | 0.135M | 0.066M | - | 0.003M | 0.025M |
| Other Current Assets | 0.833M | 1.036M | 0.696M | 0.655M | 0.556M |
| Total Liab | 14.855M | 10.141M | 9.403M | 1.653M | 2.244M |
| Total Stockholder Equity | 5.869M | 2.304M | 18.353M | 15.243M | 26.332M |
| Other Current Liab | 1.318M | 1.24M | 1.51M | 0.502M | 0.055M |
| Common Stock | 0.06M | 0.023M | 0.022M | 0.012M | 0.012M |
| Capital Stock | 0.06M | 0.023M | 0.022M | 0.012M | 0.012M |
| Retained Earnings | -145.826M | -127.198M | -108.382M | -94.135M | -82.74M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0M | - | 0.958M | 0.655M |
| Cash | 9.266M | 3.452M | 21.716M | 12.962M | 24.783M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 3.636M | 8.583M | 3.054M | 1.528M | 1.692M |
| Current Deferred Revenue | - | - | - | - | 0.604M |
| Net Debt | -4.569M | 3.991M | -15.015M | -12.418M | -23.793M |
| Short Term Debt | 0.488M | 5.924M | 0.407M | 0.515M | 0.588M |
| Short Long Term Debt | - | 5.406M | - | 0.187M | 0.181M |
| Short Long Term Debt Total | 4.697M | 7.442M | 6.701M | 0.544M | 0.99M |
| Other Stockholder Equity | 151.636M | 127.619M | 123.925M | 109.365M | 109.061M |
| Property Plant Equipment | - | - | - | 1.803M | 2.265M |
| Total Current Assets | 16.456M | 8.022M | 23.178M | 14.131M | 25.631M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 0.617M | 0.488M | 0.099M | 0.077M | 0.084M |
| Long Term Debt | 3.179M | - | 4.258M | - | - |
| Inventory | 5.74M | 3.046M | 0.667M | 0.437M | 0.208M |
| Accounts Payable | 1.83M | 1.419M | 1.138M | 0.511M | 0.446M |
| Accumulated Other Comprehensive Income | - | 1.86M | 2.787M | - | -28.577M |
| Non Currrent Assets Other | 0.94M | 0.955M | 1.087M | 0.958M | 0.655M |
| Non Current Assets Total | 4.268M | 4.423M | 4.578M | 2.764M | 2.945M |
| Capital Lease Obligations | 1.518M | 2.036M | 2.443M | 0.402M | 0.809M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | - | -0.848M | -0.193M | -0.407M | -0.307M |
| Total Cashflows From Investing Activities | -0.63M | -0.848M | -0.144M | -0.407M | -0.307M |
| Total Cash From Financing Activities | 25.135M | 2.027M | 20.179M | -0.682M | 29.698M |
| Net Income | -18.628M | -18.817M | -14.247M | -11.394M | -7.538M |
| Change In Cash | 5.815M | -18.264M | 8.754M | -11.821M | 21.461M |
| Begin Period Cash Flow | 3.452M | 21.716M | 12.962M | 24.783M | 3.322M |
| End Period Cash Flow | 9.266M | 3.452M | 21.716M | 12.962M | 24.783M |
| Total Cash From Operating Activities | -18.691M | -19.444M | -11.281M | -10.732M | -7.931M |
| Depreciation | 0.804M | 0.872M | 0.908M | 0.889M | 0.964M |
| Other Cashflows From Investing Activities | -0.105M | -0.086M | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -2.694M | -2.379M | -0.236M | -0.233M | -0.077M |
| Sale Purchase Of Stock | - | - | - | - | - |
| Other Cashflows From Financing Activities | -1.945M | 0.002M | 2.39M | -0.233M | -1.579M |
| Capital Expenditures | 0.525M | 0.762M | 0.144M | 0.407M | 0.307M |
| Change In Working Capital | -2.057M | -3.145M | 1.222M | -0.458M | -0.733M |
| Other Non Cash Items | 0.4M | 1.201M | 0.161M | 0.006M | -0.822M |
| Free Cash Flow | -19.216M | -20.206M | -11.424M | -11.139M | -8.238M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 619461 |
| 2. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 558739 |
| 3. | Fidelity Extended Market Index | 3 months ago | 221277 |
| 4. | iShares Micro-Cap ETF | 2 months ago | 135015 |
| 5. | NT Ext Equity Mkt Idx Fd - L | 2 months ago | 67038 |
| 6. | Vanguard Balanced Index Inv | 2 months ago | 58473 |
| 7. | Fidelity Series Total Market Index | 3 months ago | 55833 |
| 8. | Fidelity Total Market Index | 3 months ago | 50540 |
| 9. | NT Ext Equity Mkt Idx Fd - NL | 2 months ago | 50194 |
| 10. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 2 months ago | 39326 |
| 11. | Vanguard Instl Ttl Stck Mkt Idx Tr | 2 months ago | 38339 |
| 12. | Extended Equity Market Fund E | 5 months ago | 35678 |
| 13. | Blackrock Extended Mkt Fund CF | 3 months ago | 35678 |
| 14. | Extended Equity Market Fund B | 5 months ago | 35678 |
| 15. | Spartan Total Market Index Pool G | 3 months ago | 31447 |
| 16. | Extended Equity Market Fund K | 2 months ago | 30379 |
| 17. | Spartan Extended Market Index Pool F | 3 months ago | 29988 |
| 18. | NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 2 months ago | 26453 |
| 19. | Northern Trust Extended Eq Market Idx | 8 months ago | 23989 |
| 20. | Fidelity Nasdaq Composite Index | 3 months ago | 18182 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Dauntless Investment Group, LLC | 5 months ago | 5931890 |
| 2. | Vanguard Group Inc | 5 months ago | 1415555 |
| 3. | Geode Capital Management, LLC | 5 months ago | 389280 |
| 4. | Citadel Advisors Llc | 5 months ago | 342166 |
| 5. | Banco BTG Pactual S.A. | 5 months ago | 152155 |
| 6. | Clear Creek Investment Mgmt LLC | 5 months ago | 109656 |
| 7. | Jane Street Group LLC | 5 months ago | 107003 |
| 8. | BlackRock Inc | 8 months ago | 98748 |
| 9. | Northern Trust Corp | 8 months ago | 75362 |
| 10. | Cetera Investment Advisers | 5 months ago | 62000 |
| 11. | State Street Corp | 8 months ago | 56369 |
| 12. | HRT FINANCIAL LLC | 5 months ago | 52833 |
| 13. | Advisor Group Holdings, Inc. | 5 months ago | 47055 |
| 14. | Nwf Advisory Services Inc | 5 months ago | 47055 |
| 15. | Kovack Advisors Inc | 5 months ago | 46800 |
| 16. | TWO SIGMA SECURITIES, LLC | 5 months ago | 31163 |
| 17. | Sontag Advisory LLC | 5 months ago | 28134 |
| 18. | Two Sigma Investments LLC | 5 months ago | 26141 |
| 19. | Ocean Capital Management, LLC | 5 months ago | 25268 |
| 20. | XTX Topco Ltd | 5 months ago | 22048 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...